AR044083A1 - Compuestos con actividad anti-inflamatoria - Google Patents

Compuestos con actividad anti-inflamatoria

Info

Publication number
AR044083A1
AR044083A1 ARP040101400A ARP040101400A AR044083A1 AR 044083 A1 AR044083 A1 AR 044083A1 AR P040101400 A ARP040101400 A AR P040101400A AR P040101400 A ARP040101400 A AR P040101400A AR 044083 A1 AR044083 A1 AR 044083A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
subunit
substructure
chain
foregoing
Prior art date
Application number
ARP040101400A
Other languages
English (en)
Inventor
Mladen Mercep
Milan Mesic
Linda Tomaskovic
Stribor Marcovic
Boska Hrvacic
Oresta Makaruha
Visnja Poljak
Original Assignee
Pliva Istrazivacki Inst D O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Istrazivacki Inst D O O filed Critical Pliva Istrazivacki Inst D O O
Publication of AR044083A1 publication Critical patent/AR044083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Abstract

Se refiere también a sales y solvatos farmacéuticamente aceptables de tales compuestos preparados para procesar, y a productos intermedios para su preparación, así como para la acción terapéutica optimizada y el uso en el tratamiento de enfermedades y condiciones inflamatorias en humanos y animales. Reivindicación 1: Un compuesto de acuerdo a la fórmula (1), donde: M representa la subunidad de macrólido de la subestructura de fórmula (2), donde: R1, R2, R3, R4 y R5 son elegidos independientemente entre sí, del grupo constituido por hidrógeno alquilo C1-4, alcanoilo, alcoxicarbonilo, arilmetoxicarbonilo, arilo, arilalquilo, alquilsililo y alquilsililalcoxialquilo; RN representa el enlace covalente con X1 de la cadena L; L representa la cadena de la subestructura: -X1-(CH2)m-Q-(CH2)n-X2-, donde: X1 es -CH2- o -C(O)-; X2 es -NH- o -O-; Q es -NH- o -CH2-; los símbolos m y n, son independientemente, números enteros de 0 a 4; con la condición que si Q=NH, n no puede ser 0; D representa una subunidad anti-inflamatoria no esteroidea o una subunidad esteroidea y las sales farmacéuticamente aceptables de la anteriores y las composiciones farmacéuticamente aceptables que contienen las anteriores.
ARP040101400A 2003-04-24 2004-04-23 Compuestos con actividad anti-inflamatoria AR044083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20030324A HRP20030324A2 (en) 2003-04-24 2003-04-24 Compounds of antiinflammatory effect

Publications (1)

Publication Number Publication Date
AR044083A1 true AR044083A1 (es) 2005-08-24

Family

ID=33307078

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101400A AR044083A1 (es) 2003-04-24 2004-04-23 Compuestos con actividad anti-inflamatoria

Country Status (28)

Country Link
US (1) US7579334B2 (es)
EP (2) EP2070940B1 (es)
JP (1) JP4613366B2 (es)
KR (1) KR101107336B1 (es)
CN (1) CN100393741C (es)
AR (1) AR044083A1 (es)
AT (1) ATE518876T1 (es)
AU (1) AU2004232546B2 (es)
BR (1) BRPI0410490A (es)
CA (1) CA2523081C (es)
CL (1) CL2004000872A1 (es)
CY (2) CY1109491T1 (es)
DE (1) DE602004022047D1 (es)
DK (2) DK1633771T3 (es)
ES (2) ES2330109T3 (es)
HK (2) HK1086842A1 (es)
HR (3) HRP20030324A2 (es)
IS (2) IS2736B (es)
ME (1) MEP34708A (es)
MX (1) MXPA05011359A (es)
NO (2) NO333909B1 (es)
PL (2) PL2070940T3 (es)
PT (2) PT1633771E (es)
RS (1) RS52621B (es)
RU (1) RU2355699C2 (es)
SI (2) SI1633771T1 (es)
WO (1) WO2004094449A1 (es)
ZA (1) ZA200508388B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
EP1723159B1 (en) 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
BRPI0514254A (pt) * 2004-08-12 2008-06-03 Glaxosmithkline Zagreb uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal
US20060183696A1 (en) * 2004-08-12 2006-08-17 Pliva-Istrazivacki Institut D.O.O. Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
ES2337915T3 (es) 2004-10-27 2010-04-30 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugados con adtividad antiinflamatoria.
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
WO2007093840A2 (en) * 2006-02-15 2007-08-23 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
EP2262483A2 (en) * 2008-03-05 2010-12-22 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
CN102838660B (zh) * 2011-06-23 2016-11-02 上海市第一人民医院 一种抑制炎症免疫反应的小肽及其应用
US20140256696A1 (en) 2013-03-08 2014-09-11 Allergan, Inc. Steroid conjugates
WO2014138343A1 (en) * 2013-03-08 2014-09-12 Allergan, Inc. Antibiotic conjugates with nonsteroidal anti-inflammatory drugs
BR112015021836A2 (pt) 2013-03-08 2017-07-18 Allergan Inc conjugados de antibióticos diretamente ligados com drogas esteroides
JP2016510753A (ja) * 2013-03-08 2016-04-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ステロイド薬と結合した抗生物質共役体
WO2016013030A2 (en) 2014-07-23 2016-01-28 Sphaera Pharma Pvt. Ltd. Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956B2 (en) 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
DE3860503D1 (de) * 1987-09-03 1990-10-04 Pliva Pharm & Chem Works 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
SE9100341D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
GB9225923D0 (en) 1992-12-11 1993-02-03 Rhone Poulenc Rorer Ltd New compositions of matter
CA2149777C (en) 1992-12-24 2004-05-25 Michael John Ashton New steroids
KR970704455A (ko) 1994-08-12 1997-09-06 우에하라 아끼라 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor)
WO1996004920A1 (fr) 1994-08-12 1996-02-22 Taisho Pharmaceutical Co., Ltd. Inhibiteur de production de l'interleukine-5
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
WO2000025776A1 (en) * 1998-10-30 2000-05-11 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
IT1306205B1 (it) 1999-01-15 2001-05-30 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
HRP20000310A2 (en) 2000-05-17 2002-02-28 Pliva Farmaceutska Ind Dioniko New dibenzoazulene compounds as tumor necrosis factor inhibitors
FI110835B (fi) 2000-07-11 2003-03-31 Radiolinja Ab Menetelmä palvelunumeropuhelun tarjoamiseksi matkaviestintilaajalle ennalta määrätyllä taksalla
HRP20010018A2 (en) 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20050171342A1 (en) * 2002-02-15 2005-08-04 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1483579A4 (en) * 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION AND USE OF CONJUGATES, FORMULATION AND PHARMACEUTICAL APPLICATIONS OBTAINED FROM SUCH CONJUGATES
EP1551865B1 (en) * 2002-07-08 2009-04-22 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Hybrid molecules of macrolides with steroidal/non-steroidal anti-inflammatory molecules
PL374646A1 (en) 2002-07-08 2005-10-31 Pliva-Istrazivacki Institutt D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
CA2489402A1 (en) * 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect

Also Published As

Publication number Publication date
ES2330109T3 (es) 2009-12-04
WO2004094449A8 (en) 2005-03-31
RS20050873A (en) 2007-08-03
ATE518876T1 (de) 2011-08-15
DK2070940T3 (da) 2011-10-31
HRP20090551T1 (hr) 2010-01-31
EP2070940A1 (en) 2009-06-17
IS2736B (is) 2011-06-15
AU2004232546A1 (en) 2004-11-04
HK1129681A1 (en) 2009-12-04
NO20055535D0 (no) 2005-11-23
NO335552B1 (no) 2014-12-29
HK1086842A1 (en) 2006-09-29
CN100393741C (zh) 2008-06-11
CA2523081A1 (en) 2004-11-04
JP4613366B2 (ja) 2011-01-19
HRP20110763T1 (hr) 2011-11-30
NO20055535L (no) 2006-01-16
CA2523081C (en) 2010-08-03
KR101107336B1 (ko) 2012-01-19
SI1633771T1 (sl) 2009-12-31
ES2370371T3 (es) 2011-12-14
NO20130898L (no) 2006-01-16
EP1633771B1 (en) 2009-07-15
PT2070940E (pt) 2011-11-14
KR20060024770A (ko) 2006-03-17
HRP20030324A2 (en) 2005-02-28
WO2004094449A1 (en) 2004-11-04
MXPA05011359A (es) 2006-05-12
US20050080003A1 (en) 2005-04-14
RU2005131937A (ru) 2006-06-27
US7579334B2 (en) 2009-08-25
IS8141A (is) 2005-11-22
NO333909B1 (no) 2013-10-14
CL2004000872A1 (es) 2005-03-18
JP2006524221A (ja) 2006-10-26
RU2355699C2 (ru) 2009-05-20
PL2070940T3 (pl) 2011-12-30
EP2070940B1 (en) 2011-08-03
ZA200508388B (en) 2006-07-26
EP2070940A3 (en) 2009-11-25
CN1777619A (zh) 2006-05-24
PL1633771T3 (pl) 2009-12-31
SI2070940T1 (sl) 2011-12-30
IS8941A (is) 2010-12-29
DK1633771T3 (da) 2009-11-16
CY1111978T1 (el) 2015-11-04
BRPI0410490A (pt) 2006-06-13
AU2004232546B2 (en) 2011-06-09
CY1109491T1 (el) 2014-08-13
RS52621B (en) 2013-06-28
DE602004022047D1 (de) 2009-08-27
MEP34708A (en) 2011-05-10
PT1633771E (pt) 2009-10-20
EP1633771A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
AR044083A1 (es) Compuestos con actividad anti-inflamatoria
AR054475A1 (es) Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion
UY28150A1 (es) Agentes terapeuticos
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
UY28144A1 (es) Agentes terapéuticos
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8591701A1 (es) Derivados de pirrolopirimidina
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
PA8544901A1 (es) Derivados de oxazol
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
PE20060380A1 (es) Derivados de pirido-pirimidina en la prevencion y tratamiento de la proliferacion celular
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
AR039601A1 (es) Derivados de nitrosodifenilamina y composiciones farmaceuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologias que se caracterizan por estres oxidativo
PA8573501A1 (es) Derivados de benzoxazina y su empleo
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas
PA8582201A1 (es) Indoles 2,7-sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure